Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Abstract Pancreatic ductal adenocarcinoma (PDAC) patients frequently suffer from undetected micrometastatic disease. This clinical situation would greatly benefit from additional investigation. Therefore, we set out to identify key signalling events that drive metastatic evolution from the pancreas. We researched a gene signature that could discriminate localised PDAC from confirmed metastatic PDAC and devised a preclinical protocol using circulating cell-free DNA (cfDNA) as an early biomarker of micro-metastatic disease to validate the identification of key signalling events. Amongst actionable markers of disease progression, the PI3K pathway and a distinctive PI3Kα activation signature predict PDAC aggressiveness and prognosis. Pharmacological or tumour-restricted genetic PI3Kα-selective inhibition prevented macro-metastatic evolution by inhibiting tumoural cell migratory behaviour independently of genetic alterations. We found that PI3Kα inhibition altered the quantity and the species composition of the lipid second messenger PIP 3 produced, with selective reduction of C36:2 PI-3,4,5-P 3 . PI3Kα inactivation prevented the accumulation of protumoural CD206-positive macrophages in the tumour-adjacent tissue. Tumour-cell intrinsic PI3Kα therefore promotes pro-metastatic features that could be pharmacologically targeted to delay macro-metastatic evolution. The paper explained PROBLEM Pancreatic cancer is one of the most lethal solid cancers characterised by rapid progression after primary tumour detection by imaging. Key signalling events that specifically drives this rapid evolution into macro-metastatic disease are so far poorly understood. RESULT With two unbiased approaches to patient data analysis, higher PI3K pathway and more specifically higher PI3Kα activation signature can now be identified in the most aggressive pancreatic cancer primary tumours, that lead to earlier patient death. Our in vitro data showed that PI3Kα is a major positive regulator of tumour cell escape from the primary tumour: tumour-intrinsic PI3Kα activity enables actin cytoskeleton remodelling to escape the pancreatic tumour. We chose to use two preclinical models of pancreatic cancer to validate that PI3Kα is a target for delaying evolution of PDAC. The first one mimicked pancreatic patient micrometastatic disease that is undetected by echography and consisted in treating mice presenting echography detected primary tumours combined with increased circulating DNA as a blood biomarker of the most aggressive tumours. The second model consisted in studying the tumour cell implantation and their early proliferation in metastatic organ after injection in blood. We treated both preclinical models with a clinically relevant PI3K α-selective inhibitor (BYL-719/Alpelisib), that is currently being tested in pancreatic cancer patients (without any patient selection). We found that PI3Kα activity drives evolution of micrometastatic disease towards macro-metastatic stage in both models: inhibition of PI3Kα delayed primary tumour and micro-metastasis evolution. Finally, PI3Kα activity increases protumoural characteristics in peritumoural immune cells via tumour cell-intrinsic cytokine production that could facilitate metastatic evolution. IMPACT Circulating tumour DNA represents a strong independent biomarker linked to relapse and poor survival in solid cancer patients. A clinical study in resected PDAC patients with micrometastatic disease characterised by high circulating tumoural DNA levels is needed to assess if PI3Kα-selective inhibitors significantly delay metastatic progression and death. Graphical Abstract Pancreatic ductal adenocarcinoma requires tumour-intrinsic PI3Kα activity to accelerate inflammatory metastatic disease. Biorender illustration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · cited 2×
“…in circulating tumour DNA, progression-free survival (PFS) improvement became largely significant (Delaloge & DeForceville, 2017), and BYL-719 (alpelisib) was recently granted marketing authorisation for the treatment of breast cancer in combination with endocrine therapy (Andr e et al, 2019).”
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207 · cited 2×
“Cell-free DNA (cfDNA) and, more precisely, circulating tumour DNA (ctDNA) appears in clinical oncology as an attractive biomarker for early cancer detection, diagnosis and prognosis (Diehl et al, 2008; Dawson et al, 2013; Alix-Panabi eres & Pantel, 2016; Abdallah et al, 2020).”
EMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967
The emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767
Self-citationTherapeutic developments in pancreatic cancer: current and future perspectives
Neoptolemos, J. P., Kleeff, J., Michl, P., Costello, E., Greenhalf, W., & Palmer, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0005-x · Cited by 1,170
Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137
Self-citationWhole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115
Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis
Gao, D., Nolan, D. J., Mellick, A. S., Bambino, K., McDonnell, K., & Mittal, V. (2008) · Science · doi:10.1126/science.1150224 · Cited by 632
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Zhang, Y., Kwok-Shing Ng, P., Kucherlapati, M., Chen, F., Liu, Y., Tsang, Y. H., de Velasco, G., Jeong, K. J., Akbani, R., Hadjipanayis, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.013 · Cited by 626
Chen, Q., Zhang, X. H.-F., & Massagué, J. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.025 · Cited by 619
Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features
Puleo, F., Nicolle, R., Blum, Y., Cros, J., Marisa, L., Demetter, P., Quertinmont, E., Svrcek, M., Elarouci, N., Iovanna, J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.033 · Cited by 563 · cited 1×
“For in vitro use, all PI3K inhibitors (Knight et al, 2004; Jackson et al, 2005; Pomel et al, 2006; Ali et al, 2008; Folkes et al, 2008; Raynaud et al, 2009; Burger et al, 2011; Jamieson et al, 2011; Fritsch et al, 2014; Barlaam et al, 2015) (Dataset EV4) and the FGFR inhibitor AZD4547 were…”
Eser, S., Reiff, N., Messer, M., Seidler, B., Gottschalk, K., Dobler, M., Hieber, M., Arbeiter, A., Klein, S., Kong, B., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.023 · Cited by 360
Self-citationγδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation
Daley, D., Zambirinis, C. P., Seifert, L., Akkad, N., Mohan, N., Werba, G., Barilla, R., Torres-Hernandez, A., Hundeyin, M., Mani, V. R. K., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.046 · Cited by 329
Phosphatidylinositol 3-kinase, growth disorders, and cancer
Goncalves, M. D., Hopkins, B. D., & Cantley, L. C. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1704560 · Cited by 327
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
Hobbs, G. A., Baker, N. M., Miermont, A. M., Thurman, R. D., Pierobon, M., Tran, T. H., Anderson, A. O., Waters, A. M., Diehl, J. N., Papke, B., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1006 · Cited by 231
Shapiro, G. I., Rodon, J., Bedell, C., Kwak, E. L., Baselga, J., Braña, I., Pandya, S. S., Scheffold, C., Laird, A. D., Nguyen, L. T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1777 · Cited by 152 · cited 1×
“The tumour-intrinsic action of PI3Ka on tumour inflammation that we described here could be added to its direct immunomodulatory action in pancreatic cancer found by others (Sivaram et al, 2019).”
Li, B., Vincent, A., Cates, J., Brantley-Sieders, D. M., Polk, D. B., & Young, P. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1565 · Cited by 115
Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism
Foukas, L. C., Bilanges, B., Bettedi, L., Pearce, W., Ali, K., Sancho, S., Withers, D. J., & Vanhaesebroeck, B. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201953 · Cited by 91
Tumor-intrinsic PIK3CA represses tumor immunogenicity in a model of pancreatic cancer
Sivaram, N., McLaughlin, P. A., Han, H. V., Petrenko, O., Jiang, Y.-P., Ballou, L. M., Pham, K., Liu, C., van der Velden, A. W. M., & Lin, R. Z. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123540 · Cited by 78
Cited by
Therapeutic targeting of tumour myeloid cells
Barry, S. T., Gabrilovich, D. I., Sansom, O. J., Campbell, A. D., & Morton, J. P. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00546-2 · Cited by 305
Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress
Mehra, S., Deshpande, N., & Nagathihalli, N. (2021) · Cancers · doi:10.3390/cancers13174434 · Cited by 85
“An increase in the activation of the PI3K signaling is associated with poor overall survival in PDAC patients [16,17].”
BackgroundThibault, B., Ramos-Delgado, F., & Guillermet-Guibert, J. (2023) · Cancers · doi:10.3390/cancers15030784 · Cited by 40
Self-citation
Metadata
- Authors
- Thibault, B., Ramos‐Delgado, F., Pons‐Tostivint, E., Therville, N., Cintas, C., Arcucci, S., Cassant‐Sourdy, S., Reyes‐Castellanos, G., Tosolini, M., Villard, A. V., Cayron, C., Baer, R., Bertrand‐Michel, J., Pagan, D., Ferreira Da Mota, D., Yan, H., Falcomatà, C., Muscari, F., Bournet, B., Delord, J., Aksoy, E., Carrier, A., Cordelier, P., Saur, D., Basset, C., & Guillermet‐Guibert, J.
- Venue
- EMBO Molecular Medicine
- Published
- 2021-05-25
- Volume
- 13
- Issue
- 7
- Pages
- e13502-e13502
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W3164044183
- Cited by
- 44
- References
- 22
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.